[1]
|
Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence[J]. Nat Rev Nephrol, 2021, 17: 227-244. doi: 10.1038/s41581-020-00367-2 |
[2]
|
Kalyani RR. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes[J]. N Engl J Med, 2021, 384: 1248-1260. doi: 10.1056/NEJMcp2000280 |
[3]
|
Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes[J]. Lancet Diabetes Endocrinol, 2021, 9: 525-544. doi: 10.1016/S2213-8587(21)00113-3 |
[4]
|
Marx N, Davies MJ, Grant PJ, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care[J]. Lancet Diabetes Endocrinol, 2021, 9: 46-52. doi: 10.1016/S2213-8587(20)30343-0 |
[5]
|
Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison[J]. J Am Coll Cardiol, 2022, 79: 1849-1857. |
[6]
|
Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J]. Mol Metab, 2021, 46: 101102. doi: 10.1016/j.molmet.2020.101102 |
[7]
|
Ceriello A, Prattichizzo F, Phillip M, et al. Glycaemic management in diabetes: old and new approaches[J]. Lancet Diabetes Endocrinol, 2022, 10: 75-84. doi: 10.1016/S2213-8587(21)00245-X |
[8]
|
Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials[J]. BMJ, 2021, 372: m4573. |
[9]
|
Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications[J]. Lancet, 2021, 398: 262-276. doi: 10.1016/S0140-6736(21)00536-5 |
[10]
|
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol, 2021, 9: 653-662. doi: 10.1016/S2213-8587(21)00203-5 |
[11]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13: 315-409. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK202108007.htm |
[12]
|
Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline[J]. BMJ, 2021, 373: n1091. |
[13]
|
Marx N, Grant PJ, Cosentino F. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk[J]. Eur Heart J, 2020, 41: 329-330. doi: 10.1093/eurheartj/ehz853 |
[14]
|
He L, Yang N, Xu L, et al. Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis[J]. Diabetes Ther, 2020, 11: 2121-2143. doi: 10.1007/s13300-020-00882-2 |
[15]
|
Lee MMY, Ghouri N, McGuire DK, et al. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes[J]. Diabetes Care, 2021, 44: 1236-1241. doi: 10.2337/dc20-3007 |
[16]
|
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial[J]. JAMA, 2015, 314: 687-699. doi: 10.1001/jama.2015.9676 |
[17]
|
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management[J]. N Engl J Med, 2015, 373: 11-22. doi: 10.1056/NEJMoa1411892 |
[18]
|
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity[J]. N Engl J Med, 2021, 384: 989-1002. doi: 10.1056/NEJMoa2032183 |
[19]
|
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: the STEP 4 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1414-1425. doi: 10.1001/jama.2021.3224 |
[20]
|
Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: the STEP 3 Randomized Clinical Trial[J]. JAMA, 2021, 325: 1403-1413. doi: 10.1001/jama.2021.1831 |
[21]
|
Christensen RM, Juhl CR, Torekov SS. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists[J]. Drug Saf, 2019, 42: 957-971. doi: 10.1007/s40264-019-00812-7 |
[22]
|
US Food, Drugs Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014[EB/OL]. (2021-06-04)[2022-07-01]. https://www.fda.gov/news-events/press-announcements/fda-appro- ves-new-drug-treatment-chronic-weight-management-first-2014. |
[23]
|
Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials[J]. Diabetes Obes Metab, 2017, 19: 336-347. doi: 10.1111/dom.12824 |
[24]
|
Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study[J]. JAMA Intern Med, 2013, 173: 534-539. doi: 10.1001/jamainternmed.2013.2720 |
[25]
|
Douros A, Filion KB, Yin H, et al. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy[J]. Diabetes Care, 2018, 41: 2330-2338. doi: 10.2337/dc17-2280 |
[26]
|
Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106: 912-921. doi: 10.1210/clinem/dgaa891 |
[27]
|
Pizzimenti V, Giandalia A, Cucinotta D, et al., Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database[J]. J Clin Pharm Ther, 2016, 41: 116-118. doi: 10.1111/jcpt.12373 |
[28]
|
Faillie JL, Yu OH, Yin H, et al. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus[J]. JAMA Intern Med, 2016, 176: 1474-1481. doi: 10.1001/jamainternmed.2016.1531 |
[29]
|
Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined[J]. N Engl J Med, 2021, 384: 1719-1730. doi: 10.1056/NEJMoa2028198 |
[30]
|
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial[J]. Lancet, 2017, 389: 1399-1409. doi: 10.1016/S0140-6736(17)30069-7 |
[31]
|
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375: 1834-1844. doi: 10.1056/NEJMoa1607141 |
[32]
|
Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial[J]. Diabetes Care, 2019, 42: 1912-1920. doi: 10.2337/dc19-0415 |
[33]
|
He L, Zhang H. Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2021, 385: 2106-2107. |
[34]
|
He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials[J]. JAMA Intern Med, 2022, 182: 513-519. doi: 10.1001/jamainternmed.2022.0338 |
[35]
|
Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study[J]. BMJ, 2018, 363: k4880. |
[36]
|
Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss[J]. Am J Surg, 1995, 169: 91-96; discussion 96-97. doi: 10.1016/S0002-9610(99)80115-9 |
[37]
|
Shiffman ML, Kaplan GD, Brinkman-Kaplan V, et al. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program[J]. Ann Intern Med, 1995, 122: 899-905. doi: 10.7326/0003-4819-122-12-199506150-00002 |
[38]
|
He L, Wang J, Ping F, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials[J]. BMJ, 2022, 377: e068882. |